CEO and President by the board of directors and was instrumental in selling the company.
Mr. Pierce also worked as a consultant for LifeScience Economics where he advised mutual funds, hedge funds, venture capital funds, biotech, pharmaceutical, medical device and technology companies on venture investments, investor relations issues and strategic partnering activities. Among the companies he counseled while at LifeScience Economics include H&Q Capital Management (NYSE:HQL, NYSE: HQH), Neurobiological Technologies (NASDAQ: NTII), Bioject, Inc. (NASDAQ: BJCT) and SafeScience, Inc. (NASDAQ: SAFS), the predecessor company of GlycoGenesys.
Prior to consulting, Mr. Pierce was Sr. VP Finance & Business Development of LADIA, LLC, where he was recruited to lead business development and financing strategy of early Internet start-up companies. He was responsible for developing institutional financing strategy that led to attracting venture capital funding from Pennsylvania Merchants Group’s Eagle Fund of $10 million. Mr. Pierce led all business development efforts leading to purchase by Computone, Inc. (NASDAQ: CMPT).
Full biographies, unique experience, expertise & accomplishments of each advisory board member:
- Neil J. Campbell,
M.A., M.B.A. – Chairman - Kevin Carroll
- Edward L. Erickson
- Daniel D'Agostino
- Nigel Gaymond, M.A.
- David M. Koeninger
- Udo Klein, Ph.D.
- Stefan Loren, Ph.D.
- Kevin Nickels
- Rick Pierce
- Robin Pratt, Ph.D.
- Linda M. Pullan, Ph.D.
- Dane Saglio, C.P.A.
- Peter G. Savas
- Chris Ward
- Ruth Williams, Esq.
Rick Pierce is Vice President, Investor Relations of Javelin Pharmaceuticals, Inc., (NYSE Amex: JAV) a specialty pharmaceutical company committed to the development of new drugs and improved formulations of existing drugs that target current unmet and underserved medical need in the pain management market. Mr. Pierce joined Javelin in July 2006 to help expand the US and European shareholder base. In 3.5 years, he successfully increased institutional and high net worth shareholders from 650 to more than 7,500. Mr. Pierce is responsible for the company’s investor and public relations functions and acts as the designated spokesperson to equity analysts, the press and institutional and individual shareholders. He has 25 years of diversified industry experience including specialty pharmaceuticals, biotechnology, investment banking, and equity sales and trading.
Prior to Javelin Pharmaceuticals, Mr. Pierce served as Vice President of Business Development & Finance at GlycoGenesys, Inc. (NASDAQ: GLGS) where he was responsible for the company’s in-licensing and out-licensing strategy and business development efforts. During his eight years at GLGS, Mr. Pierce was intimately involved in negotiating and closing a $30 million joint venture with Elan Pharmaceuticals (NYSE: ELN) for the company’s lead drug compound GCS-100 in the field of oncology. He was later appointed Interim
 |
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|||||||||